Hemato Oncology Testing Market, 2024 by Product & Services (Assay Kits, Services), Cancer (Leukemia, Non-Hodgkin's Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - ResearchAndMarkets.com

DUBLIN--()--The "Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia, Non-Hodgkin's Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The Hemato Oncology Testing Market is Projected to Reach USD 4.0 Billion By 2024 from USD 2.0 Billion in 2019, at a CAGR of 14.8%

Growth in this market is mainly driven by the rising incidences & prevalence of leukemia, increasing collaborations for developing new assay kits, and the growing focus on personalized medicine.

Services accounted for the larger share of the hemato oncology testing market in 2018

Based on product & service, the market is segmented into assay kits and services. In 2018, the services segment accounted for a larger share of this market majorly due to the high prevalence of leukemia & lymphoma. The market is set to grow on account of increasing collaborations between hemato oncology testing product manufacturers and pharmaceutical companies.

Leukemia accounted for the largest share of the hemato oncology testing market in 2018

Based on cancer type, the hemato oncology testing market has been segmented into three types - leukemia, lymphoma, and other cancers. Leukemia accounted for the largest share in 2018 and is anticipated to witness the highest growth rate during the forecast period due to the need for continuous monitoring of leukemia patients. In addition, increasing awareness about checking the status of minimal residual disease (MRD) in leukemia patients is another factor supporting market growth.

North America dominates the hemato oncology testing market

North America, which includes the US and Canada, accounted for the largest share of the hemato oncology testing in 2018. The large share of this market segment can be attributed to the availability of reimbursement for hemato oncology testing products, increasing awareness regarding advanced treatment theories, and the strong presence of industry players in the region.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

4.1 Hemato-Oncology Testing: Market Overview

4.2 North America: Hemato-Oncology Testing Market, By Product and Service (2018)

4.3 Geographical Snapshot of the Hemato-Oncology Testing Market

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 Increasing Incidence of Hematologic Cancer

5.2.1.2 Increasing Collaborations

5.2.1.3 Increasing Conferences on Personalized Medicine

5.2.2 Opportunities

5.2.2.1 Drug Diagnostics Co-Development

5.2.2.2 Emerging Markets

5.2.3 Restraints

5.2.3.1 Uncertain Reimbursement Scenario in Different Regions

5.2.3.2 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests

5.2.4 Challenges

5.2.4.1 Intellectual Property Rights Protection Issues

6 Hemato-Oncology Testing Market, By Product & Service

6.1 Introduction

6.2 Services

6.2.1 Rising Incidence of Hematologic Cancer to Increase the Demand for Hemato-Oncology Services

6.3 Assay Kits

6.3.1 Growing Focus on the Development of Advanced Assay Kits to Drive the Growth of This Market Segment

7 Hemato-Oncology Testing Market, By Cancer Type

7.1 Introduction

7.2 Leukemia

7.2.1 Acute Myeloid Leukemia

7.2.1.1 Aml is the Most Common Acute Leukemia Affecting Adults

7.2.2 Acute Lymphocytic Leukemia

7.2.2.1 North America Accounted for the Largest Share of the All Segment

7.2.3 Other Leukemias

7.3 Lymphoma

7.3.1 Non-Hodgkin Lymphoma

7.3.1.1 Non-Hodgkin Lymphoma Holds the Largest Share of the Market for Lymphoma

7.3.2 Hodgkin Lymphoma

7.3.2.1 APAC Hemato-Oncology Testing Market for Hodgkin Lymphoma Will Grow at the Highest Rate

7.4 Other Cancers

8 Hemato-Oncology Testing Market, By Technology

8.1 Introduction

8.2 PCR

8.2.1 PCR Accounted for the Largest Share of the Hemato-Oncology Testing Market in 2018

8.3 IHC

8.3.1 IHC Accounted for the Second-Largest Share of the Hemato-Oncology Testing Market

8.4 NGS

8.4.1 NGS is Expected to Register the Highest Growth During the Forecast Period

8.5 Cytogenetics

8.5.1 North America Accounted for the Largest Share of the Cytogenetics Market

8.6 Other Technologies

9 Hemato-Oncology Testing Market, By End User

9.1 Introduction

9.2 Clinical Laboratories

9.2.1 Presence of Robust Infrastructure is the Major Driving Factor for This Segment

9.3 Hospitals

9.3.1 Hospitals Accounted for the Second-Largest Share of the Market, By End User

9.4 Academic & Research Institutes

9.4.1 APAC Market for Academic & Research Institutes Will Grow at the Highest Rate

9.5 Other End Users

10 Hemato-Oncology Testing Market, By Region

10.1 Introduction

10.2 North America

10.2.1 US

10.2.1.1 The US Dominates the North American Hemato-Oncology Testing Market

10.2.2 Canada

10.2.2.1 Initiatives Undertaken By Healthcare Authorities in the Country to Ensure the Delivery of Better Public Healthcare to Support the Growth of the Hemato-Oncology Testing Market in Canada

10.3 Europe

10.3.1 Rising Focus on Biomarker Development in EU Countries to Support Market Growth

10.4 Asia Pacific

10.4.1 Asia Pacific Market to Witness the Highest Growth During the Forecast Period

10.5 Rest of the World

11 Competitive Landscape

11.1 Overview

11.2 Market Ranking Analysis, 2017

11.3 Key Strategies

11.3.1 Product Launches & Approvals, 2016-2019

11.3.2 Expansions, 2016-2019

11.3.3 Partnerships and Collaborations, 2016-2019

11.3.4 Acquisitions, 2016-2019

12 Company Profiles

12.1 F. Hoffman-La Roche Ltd.

12.2 Abbott Laboratories

12.3 Qiagen N.V.

12.4 Thermo Fisher Scientific, Inc.

12.5 Illumina, Inc.

12.6 Bio-Rad Laboratories, Inc.

12.7 Molecularmd (Subsidiary of Icon PLC)

12.8 Archerdx, Inc.

12.9 Arup Laboratories Inc.

12.10 Asuragen, Inc.

12.11 Invivoscribe, Inc.

12.12 Adaptive Biotechnologies.

For more information about this report visit https://www.researchandmarkets.com/r/lqwuyv

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics, Oncology

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics, Oncology